The Elimination Of Hepatitis C As A Global Public Health Threat
Funder
National Health and Medical Research Council
Funding Amount
$7,001,475.00
Summary
In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2 ....In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2030.Read moreRead less
Protein Glycan Interactions In Infectious Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$9,182,220.00
Summary
Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st centu ....Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st century.Read moreRead less
Optimising Heart Disease Prevention And Management
Funder
National Health and Medical Research Council
Funding Amount
$4,647,175.00
Summary
As we become older and risk factors such as obesity become more common, our biggest contributor to death and disability, cardiovascular disease (including heart disease), will continue to exert an enormous burden on our health care system and society. We will extend our ground-breaking research on multidisciplinary teams to create new and innovative health care programs to optimise the prevention and management of new heart disease and chronic forms of heart disease.
Tropical Diseases: Translating Discoveries Into Better Health
Funder
National Health and Medical Research Council
Funding Amount
$19,803,660.00
Summary
Major progress being made in control of many infectious diseases occurring in tropical areas, including malaria worms and the bacteria that causes strep throat. However, currently available tools will not permit their full control or elimination. This program is aimed to improve understanding of these diseases and to develop the much needed tools that will be required for their elimination.
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
Drug-related deaths in Australia account for 6.6% of all deaths (ABS 2009). In much of the rural Asia-Pacific, pesticide poisoning and snakebite are major problems. We propose an integrated and international human toxicology research program covering medicine and chemical poisoning, serious adverse drug reactions, snake and spider bite. Our focus is on the applied research needed to detect new problems and rapidly translate early findings into better treatment, regulations & policy.
Addressing The Major Challenges In HIV Vaccine And Cure Research
Funder
National Health and Medical Research Council
Funding Amount
$16,136,755.00
Summary
HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections each year. Despite advances in management of HIV infection with antiretroviral therapy, there is still no cure, no effective vaccine, and several co-infections reduce life expectancy. This program assembles Australia’s leading HIV researchers to use innovative basic and translational science to tackle priority areas in controlling the HIV epidemic.
Dengue, Zika and Chikungunya are viral diseases transmitted to humans by mosquitoes. Our research uses a naturally-occurring bacteria, Wolbachia, to stop mosquitoes transmitting these viruses to humans. Our proposal addresses critical knowledge gaps in the biology of mosquitoes and Wolbachia to enable large-scale field-deployment optimisation in affected countries. The outcome of our research will immediately translate to disease control efforts in northern Australia, Asia and Latin America.
At least 6 young Australians are diagnosed each day with type 1 diabetes. This Program aims to change the way type 1 diabetes is managed by proactively treating its underlying mechanisms. We will develop safer and more effective immune therapies, develop islet transplantation, look for better markers of disease, and identify ways to preserve insulin-producing cells. The Program aims to propel type 1 diabetes research forward to reach the goals of prevention and cure.
Stroke outcomes directly relate to brain tissue rescue. We have contributed to changes in clinical practice through many clinical trials of new protocols and therapeutic strategies. Our program will focus on brain salvage in the pre-hospital setting and the acute hospital environment. We will use novel approaches to enhance brain recovery and design new implementation strategies to maximise the benefits of these therapeutic advances.